O	0	8	RESEARCH	RESEARCH	NN	B-NP
O	9	15	DESIGN	DESIGN	NN	I-NP
O	16	19	AND	AND	CC	I-NP
O	20	27	METHODS	METHODS	NNS	I-NP

O	28	31	For	For	IN	B-PP
O	32	36	this	this	DT	B-NP
O	37	42	study	study	NN	I-NP
O	42	43	,	,	,	O
O	44	46	20	20	CD	B-NP
O	47	58	individuals	individual	NNS	I-NP
O	59	60	(	(	(	O
O	60	64	mean	mean	JJ	B-NP
O	65	68	age	age	NN	I-NP
O	69	71	39	39	CD	I-NP
O	71	72	.	.	.	O
O	72	73	5	5	CD	B-NP
O	74	75	+	+	SYM	O
O	75	76	/	/	SYM	O
O	76	77	-	-	SYM	B-NP
O	78	80	11	11	CD	B-NP
O	80	81	.	.	SYM	I-NP
O	81	82	1	1	CD	I-NP
O	83	88	years	year	NNS	I-NP
O	88	89	)	)	)	O
O	90	94	with	with	IN	B-PP
O	95	99	long	long	RB	B-ADVP
O	99	100	-	-	HYPH	O
O	100	108	standing	stand	VBG	B-VP
O	109	113	type	type	NN	B-NP
O	114	115	1	1	CD	I-NP
O	116	124	diabetes	diabetes	NN	I-NP
O	125	126	(	(	(	O
O	126	128	21	21	CD	B-NP
O	128	129	.	.	.	O
O	129	130	3	3	CD	B-NP
O	131	132	+	+	SYM	O
O	132	133	/	/	SYM	O
O	133	134	-	-	SYM	B-NP
O	135	137	10	10	CD	B-NP
O	137	138	.	.	SYM	I-NP
O	138	139	7	7	CD	I-NP
O	140	145	years	year	NNS	I-NP
O	145	146	)	)	)	O
O	147	151	were	be	VBD	B-VP
O	152	160	enrolled	enrol	VBN	I-VP
O	161	163	in	in	IN	B-PP
O	164	168	this	this	DT	B-NP
O	169	180	prospective	prospective	JJ	I-NP
O	181	185	open	open	JJ	I-NP
O	185	186	-	-	HYPH	I-NP
O	186	191	label	label	NN	I-NP
O	192	201	crossover	crossover	NN	I-NP
O	202	207	trial	trial	NN	I-NP
O	207	208	.	.	.	O

O	209	214	After	After	IN	B-PP
O	215	224	achieving	achieve	VBG	B-VP
O	225	232	optimal	optimal	JJ	B-NP
B-Organism_substance	233	238	blood	blood	NN	I-NP
O	239	246	glucose	glucose	NN	I-NP
O	247	254	control	control	NN	I-NP
O	254	255	,	,	,	O
O	256	258	16	16	CD	B-NP
O	259	267	subjects	subject	NNS	I-NP
O	268	272	were	be	VBD	B-VP
O	273	283	randomized	randomize	VBN	I-VP
O	284	286	to	to	TO	B-VP
O	287	296	exenatide	exenatide	VB	I-VP
O	297	301	with	with	IN	B-PP
O	302	304	or	or	CC	I-PP
O	305	312	without	without	IN	I-PP
O	313	323	daclizumab	daclizumab	NN	B-NP
O	323	324	.	.	.	O

O	325	335	Endogenous	Endogenous	JJ	B-NP
O	336	343	insulin	insulin	NN	I-NP
O	344	354	production	production	NN	I-NP
O	355	358	was	be	VBD	B-VP
O	359	369	determined	determine	VBN	I-VP
O	370	372	by	by	IN	B-PP
O	373	383	repeatedly	repeatedly	RB	B-VP
O	384	393	measuring	measure	VBG	I-VP
B-Organism_substance	394	399	serum	serum	NN	B-NP
O	400	401	C	C	NN	I-NP
O	401	402	-	-	HYPH	B-NP
O	402	409	peptide	peptide	NN	I-NP
O	409	410	.	.	.	O

